Imaging Core

成像核心

• 批准号: 10620686
• 负责人: BRADFORD C DICKERSON
• 金额: $ 24.3万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10620686
• 关键词: Acceleration; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Award; Biological Markers; Blood Vessels; Classification; Clinical; Collaborations; Communication; Comparative Study; Data; Data Set; Development; Diagnosis; Diagnostic; Differential Diagnosis; Early Diagnosis; Early Onset Alzheimer Disease; Education; Ensure; Evaluation; Faculty; Fiber; Frontotemporal Lobar Degenerations; Functional Magnetic Resonance Imaging; Funding; Future; Goals; Grant; Heterogeneity; Human Resources; Image; Image Analysis; Individual; Industry; Inherited; Injury; International; Intervention Trial; Link; Liquid substance; MRI Scans; Machine Learning; Magnetic Resonance Imaging; Massachusetts; Measures; Methods; Mission; Monitor; Multi-Institutional Clinical Trial; Multimodal Imaging; Nerve Degeneration; Outcome; Participant; Pattern; Phenotype; Positron-Emission Tomography; Process; Protocols documentation; Radiopharmaceuticals; Research; Research Personnel; Research Project Grants; Resources; Scanning; Software Tools; Students; Syndrome; Techniques; Tissues; Tracer; Training; United States National Institutes of Health; Validation; Work; analytical method; analytical tool; biological research; career; cerebral atrophy; clinical practice; cohort; connectome; cost effective; data tools; disease heterogeneity; image archival system; imaging facilities; imaging modality; innovation; interest; multidisciplinary; neuroimaging; neuroimaging marker; neuroinflammation; neuropathology; next generation; novel; preclinical study; prognostication; recruit; research study; tau Proteins; vascular injury; virtual; white matter

Massachusetts Alzheimer's Disease Research Center: Imaging Core The Imaging Core of the Massachusetts Alzheimer's Disease Research Center (MADRC) supports and performs imaging research to understand a variety of types of heterogeneity in Alzheimer's disease and Alzheimer's disease related disorders (AD/ADRD) and accelerate progress towards a cure. We carry out core functions in Aims 1, 2, and 3 marshaling resources to enhance the research mission through the support and contributions to imaging components of MADRC-affiliated local and national research projects and the development of uniform imaging protocols that contribute to novel efforts to understand heterogeneity, such as the classification of MADRC Research Cohort participants into the "ATVN" (amyloid, tau, vascular, neurodegeneration) biological research framework. In Aims 4, 5, and 6, we develop and implement new strategies and accelerate progress towards a cure in our refinement and validation of novel PET and structural and functional MRI methods. These innovative imaging methods are evaluated in the MADRC Research Cohort, leveraging this deeply phenotyped cohort of participants spanning diverse AD/ADRD diagnoses to make the process of innovation cost-effective (many participants have already been imaged and so these measures can be used to facilitate strategic recruitment; e.g., of amyloid “positive” subjects) and value-added (by comparing novel imaging measures with those we understand well already). In Aims 7 and 8 we build the future by providing expertise, education, training and data and software tools to faculty, trainees and students for best practices in imaging research and by providing education to researchers, clinicians and the public on the advances, utility and responsible interpretation of imaging data in AD and ADRD research and ultimately clinical practice.

马萨诸塞州阿尔茨海默病研究中心：影像核心 马萨诸塞州阿尔茨海默病研究中心(MADRC)的成像核心支持和 进行影像研究以了解阿尔茨海默病的各种类型的异质性和 与阿尔茨海默病相关的疾病(AD/ADRD)和加速治疗进展。我们执行 目标1、2和3中的核心功能编组资源，以通过 支持和贡献MADRC附属的地方和国家研究项目的成像部分以及 统一成像协议的发展有助于理解异质性的新努力，如 作为MADRC研究队列参与者的分类，将其归入“ATVN”(淀粉样蛋白，tau，血管， 神经退行性变)生物学研究框架。在目标4、5和6中，我们开发和实现新的 战略和加速的进展，在我们的改进和验证的新型聚酯和 结构和功能MRI方法。这些创新的成像方法在MADRC中进行了评估 研究队列，利用横跨不同AD/ADRD的这一深入表型的参与者队列 诊断以使创新过程具有成本效益(许多参与者已经进行了成像和 因此，这些措施可用于促进战略性招募；例如，淀粉样蛋白“阳性”受试者)和 增值(通过将新的成像措施与我们已经很了解的措施进行比较)。在目标7和目标8中 我们通过为教职员工、学员提供专业知识、教育、培训以及数据和软件工具来建设未来 和学生在成像研究方面的最佳实践，并通过向研究人员、临床医生和 公众对AD和ADRD研究中成像数据的进展、用途和负责任的解释 以及最终的临床实践。